Organogenesis provides update on Phase 3 trial of ReNu in knee osteoarthritis
Organogenesis (ORGO) announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a ...
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2024. Organogenesis ( ORGO -1.43%) Q3 2024 Earnings Call Nov 12, 2024, ...
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...
Yahoo Finance10d
Organogenesis Holdings And 2 Other US Penny Stocks To Watch
Overview: Organogenesis Holdings Inc. is a regenerative ... Recent developments include a significant advancement in their ReNu® program for knee osteoarthritis treatment and filing a US$250 ...
Morningstar3d
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
“We have passed another critical milestone in the ReNu development program,” said Patrick Bilbo, Chief Operating Officer of Organogenesis. “We are pleased with the outcome of the interim ...